Ashit K. Ganguly, Ph.D.

Prof. A. K. Ganguly was born in India and educated both in India and in England. He received his Ph.D. degree from Imperial College, London under the supervision of Sir Derek Barton.
Prof. Ganguly immigrated to the United States in 1967 and worked with Sir Derek at the Research Institute of Medicine and Chemistry, Cambridge, Massachusetts before joining the Schering-Plough Research Institute, Kenilworth, NJ in 1968 as a Senior Scientist. At Schering-Plough Research Institute he progressed to the position of Senior Vice President of Chemical Research in which capacity he directed all aspects of Chemical Research at the Institute. In September 1999 he retired from Schering-Plough and joined the Stevens Institute of Technology, Hoboken, NJ as a Distinguished Research Professor of Chemistry where he currently teaches Medicinal Chemistry and directs research programs for graduate students.
Prof. Ganguly has made many significant contributions in drug discovery. He is associated with the discovery of ezetimibe (Zetia), a cholesterol absorption inhibitor; posaconazole (Noxafil), a potent antifungal; boceprevir (Victrelis), a potent antiviral agent that inhibits HCV protease, and lonafarnib (Sarasar), a highly selective farnesyl protein transferase inhibitor that is under development for progeria.
Prof. Ganguly is recognised for his contributions towards synthesis of many other biologically active molecules and determining structures of complex oligosaccharide antibiotics such as Ziracin; a macrolide antibiotic, rosaramicin, and a cyclic-peptide thiostrepton analog. His work on beta-lactam antibiotics, particularly in the area of penems, is widely cited.
Prof. Ganguly is a co-inventor on 90 patents and is a co-author on 215 scientific publications. He has been a plenary lecturer at many international meetings and is the recipient of several awards, including:
2003, American Chemical Society: E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances
2004, Stevens Institute of Technology, Doctor of Engineering, Honoris Causa
2004, Indian Chemical Society, Lifetime achievement award
2006, Thomas Alva Edison Award
2007, A.C.S., "Hall of Fame," Medicinal Chemistry
2011, Topliss Lecture on the advances in Medicinal Chemistry at the University of Michigan.
Prof. Ganguly consults for pharmaceutical and biopharmaceutical clients in the US, Canada and the UK and has been a member of several scientific advisory boards.
Prof. Ganguly immigrated to the United States in 1967 and worked with Sir Derek at the Research Institute of Medicine and Chemistry, Cambridge, Massachusetts before joining the Schering-Plough Research Institute, Kenilworth, NJ in 1968 as a Senior Scientist. At Schering-Plough Research Institute he progressed to the position of Senior Vice President of Chemical Research in which capacity he directed all aspects of Chemical Research at the Institute. In September 1999 he retired from Schering-Plough and joined the Stevens Institute of Technology, Hoboken, NJ as a Distinguished Research Professor of Chemistry where he currently teaches Medicinal Chemistry and directs research programs for graduate students.
Prof. Ganguly has made many significant contributions in drug discovery. He is associated with the discovery of ezetimibe (Zetia), a cholesterol absorption inhibitor; posaconazole (Noxafil), a potent antifungal; boceprevir (Victrelis), a potent antiviral agent that inhibits HCV protease, and lonafarnib (Sarasar), a highly selective farnesyl protein transferase inhibitor that is under development for progeria.
Prof. Ganguly is recognised for his contributions towards synthesis of many other biologically active molecules and determining structures of complex oligosaccharide antibiotics such as Ziracin; a macrolide antibiotic, rosaramicin, and a cyclic-peptide thiostrepton analog. His work on beta-lactam antibiotics, particularly in the area of penems, is widely cited.
Prof. Ganguly is a co-inventor on 90 patents and is a co-author on 215 scientific publications. He has been a plenary lecturer at many international meetings and is the recipient of several awards, including:
2003, American Chemical Society: E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances
2004, Stevens Institute of Technology, Doctor of Engineering, Honoris Causa
2004, Indian Chemical Society, Lifetime achievement award
2006, Thomas Alva Edison Award
2007, A.C.S., "Hall of Fame," Medicinal Chemistry
2011, Topliss Lecture on the advances in Medicinal Chemistry at the University of Michigan.
Prof. Ganguly consults for pharmaceutical and biopharmaceutical clients in the US, Canada and the UK and has been a member of several scientific advisory boards.